Laura Kyle
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 12
-
- Ultrasound in Clinical Applications 2
Laura Kyle
15 papers receiving 2k citations
Laura Kyle's Hit Papers
Peers
Comparison fields: 5 of 86
- Infectious Diseases 1.5k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 44
- Statistics and Probability 76
- Hematology 56
Countries citing papers authored by Laura Kyle
This map shows the geographic impact of Laura Kyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Kyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Kyle more than expected).
Fields of papers citing papers by Laura Kyle
This network shows the impact of papers produced by Laura Kyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Kyle. The network helps show where Laura Kyle may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | 2021 | 166 | |
| 7 | 2022 | 105 | |
| 8 | 2022 | 100 | |
| 9 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 10 | 2023 | 46 | |
| 11 | 2023 | 34 | |
| 12 | 2023 | 25 | |
| 13 | 2024 | 24 | |
| 14 | 2024 | 11 | |
| 15 | 2025 | 5 | |
| 16 | 2024 | 0 |
About Laura Kyle
Laura Kyle is a scholar working on Infectious Diseases, Critical Care and Intensive Care Medicine, Nutrition and Dietetics, Surgery and Nuclear Energy and Engineering, having authored 16 papers that have together received 2.1k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (12 papers), Ultrasound in Clinical Applications (2 papers), Vitamin C and Antioxidants Research (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (1.5k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (44 citations), Statistics and Probability (76 citations) and Hematology (56 citations). Laura Kyle has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, JAMA, Intensive Care Medicine, The Lancet Infectious Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.